SUBSCRIBE NEWSLETTER
  • Change Language
  • English
  • Hindi
  • Marathi
  • Gujarati
  • Punjabi
  • Tamil
  • Telugu
  • Bengali
  • News From Press Return Tracker: Solid show by pharma funds

    Return Tracker: Solid show by pharma funds

    Many of the pharma stocks have been multi-baggers
    Source: HBL Jan 25, 2016

    Many of the pharma stocks have been multi-baggers

    The BSE Healthcare index, which was on a bull run since early 2012, came to a halt in April 2015 and has been in a sideways consolidation phase lately. However, it continues to outperform the Sensex over five- and 10-year periods. This outperformance is mainly due to a strong rally during 2009 and 2010 as well as an accelerated rally between 2012 and 2014. Many pharma and healthcare stocks in this rally became multi-baggers.

    This is reflected in the pharma and healthcare funds as well, which have delivered a category average return of 5.8 per cent, 27.2 per cent and 20 per cent over one, three and five-year periods, respectively. In these periods, they have comfortably outpaced the BSE Healthcare index by 2 to 5 percentage points.
    SBI Pharma leads

    There are four funds in the pharma sector — Reliance Pharma, SBI Pharma, UTI Pharma & Healthcare and Tata India Pharma & HealthCare launched in December 2015.

    SBI Pharma leads the category over one, three and five-year periods. The scheme’s picks in the mid and small-caps space helped performance over the past year. For instance, Bengaluru-based Sequent Scientific’s stock price has more than doubled in the last one year. Likewise, other small mid-cap stocks that boosted the scheme’s performance include Natco Pharma, Aurobindo Pharma and Strides Shasun.

    The fund exited Dr Reddy’s Laboratories following regulatory issues at three of its manufacturing facilities; this helped the fund contain the downside better than its benchmark – BSE Healthcare Index.

    Reliance Pharma ranks second, clocking 10 per cent over a one-year time-frame. The fund loaded up on Abbott India, which provided a leg-up to its performance. Other large-cap names that aided performance include Sanofi India, Divi’s Laboratories and Biocon. The rally in mid-cap stocks, such as Aurobindo Pharma and FDC, also helped spice up returns. The fund was a buyer in the recently-listed pharma and healthcare stocks – Alkem Laboratories, Dr Lal PathLabs and Narayana Hrudayalaya.

    Click here to read more.

    Have a query or a doubt?
    Need a clarification or more information on an issue?
    Cafemutual welcomes all mutual fund and insurance related questions. So write in to us at newsdesk@cafemutual.com

    Click to clap
    Disclaimer: Cafemutual is an industry platform of mutual fund professionals. Our visitors are requested to maintain the decorum of the platform when expressing their thoughts and commenting on articles. Viewers are advised to refrain from making defamatory allegations against individuals. Those making abusive language or defamatory allegations will be blocked from accessing the web site.
    0 Comment
    Be the first to comment.
    Login or Sign up to post comments.
    More than 2,07,000 of your industry peers are staying on top of their game by receiving daily tips, ideas and articles on growth strategies. Join them and stay updated by subscribing to Cafemutual newsletters.

    Fill in the below details or write to newsdesk@cafemutual.com and subscribe to Cafemutual Newsletter now.
    Cafemutual is an independent media platform and focuses on providing knowledge and information for the benefit of finance professionals. We do not promote any particular brand or asset category.